ArticleFrontiers in pharmacology2026
Patchouli alcohol suppresses
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Purpose: We hypothesized that HP infection suppresses the activity of the pregnane X receptor (PXR), thereby relieving its inhibitory effect on Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT), promoting gastric cancer invasiveness. PA was proposed as a PXR agonist capable of counteracting HP-induced malignant phenotypes via modulation of the PXR-Wnt/EMT axis. Methods: A multi-level integrative approach was employed: (1) single-cell transcriptomic analysis to characterize expression and regulatory features of the PXR-Wnt-EMT axis in HP-positive versus HP-negative gastric cancer epithelial cells; (2) virtual knockout and TCGA-STAD cohort analyses to assess the causal relationship between PXR and Wnt/EMT signaling; (3) molecular docking and 100 ns molecular dynamics simulations to evaluate PA binding to the PXR ligand-binding domain (LBD) and complex stability; (4) metabolomic and proteomic analyses in HP-associated gastric cancer models to validate PA-mediated modulation of metabolic networks and Wnt/EMT signaling. Results: Single-cell analysis revealed that HP-positive epithelial cells exhibited reduced PXR activity alongside upregulation of Wnt/β-catenin signaling and EMT transcription factors. Virtual PXR knockout recapitulated Wnt/EMT transcriptional activation, and TCGA-STAD analysis confirmed a significant negative correlation between PXR activity and Wnt/EMT signaling. Molecular docking and MD simulations demonstrated stable binding of PA to the PXR LBD. Metabolomic profiling revealed disrupted bile acid and lipid metabolism in HP model mice, partially restored by PA treatment. Proteomic and immunofluorescence analyses showed that PA downregulated Wnt pathway proteins (Dvl3, Tcf7l2) and mesenchymal EMT markers (N-cadherin, MMP9) while upregulating the Wnt inhibitor APC and epithelial marker E-cadherin, collectively reversing HP-induced Wnt/EMT hyperactivation. Conclusion: PA activates PXR through both direct and indirect mechanisms, thereby suppressing Wnt/β-catenin signaling and EMT, and ultimately inhibiting the initiation and progression of H. pylori-associated gastric cancer. This study elucidates the molecular link between HP-induced PXR downregulation and aberrant Wnt/EMT activation, highlighting PA as a potential therapeutic and preventive candidate for HP-related gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.